Literature DB >> 21571025

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Oliver Koeberling1, Anja Seubert, George Santos, Annalisa Colaprico, Mildred Ugozzoli, John Donnelly, Dan M Granoff.   

Abstract

We previously investigated immunogenicity of meningococcal native outer membrane vesicle (NOMV) vaccines prepared from recombinant strains with attenuated endotoxin (ΔLpxL1) and over-expressed factor H binding protein (fHbp) in a mouse model. The vaccines elicited broad serum bactericidal antibody responses. While human toll-like receptor 4 (TLR-4) is mainly stimulated by wildtype meningococcal endotoxin, mouse TLR-4 is stimulated by both the wildtype and mutant endotoxin. An adjuvant effect in mice of the mutant endotoxin would be expected to be much less in humans, and may have contributed to the broad mouse bactericidal responses. Here we show that as previously reported for humans, rhesus primate peripheral blood mononuclear cells incubated with a NOMV vaccine from ΔLpxL1 recombinant strains had lower proinflammatory cytokine responses than with a control wildtype NOMV vaccine. The cytokine responses to the mutant vaccine were similar to those elicited by a detergent-treated, wildtype outer membrane vesicle vaccine that had been safely administered to humans. Monkeys (N=4) were immunized beginning at ages 2-3 months with three doses of a NOMV vaccine prepared from ΔLpxL1 recombinant strains with over-expressed fHbp in the variant 1 and 2 groups. The mutant NOMV vaccine elicited serum bactericidal titers≥1:4 against all 10 genetically diverse strains tested, including 9 with heterologous PorA to those in the vaccine. Negative-control animals had serum bactericidal titers<1:4. Thus, the mutant NOMV vaccine elicited broadly protective serum antibodies in a non-human infant primate model that is more relevant for predicting human antibody responses than mice.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571025      PMCID: PMC3114263          DOI: 10.1016/j.vaccine.2011.04.095

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  Human Toll-like receptor 4 recognizes host-specific LPS modifications.

Authors:  Adeline M Hajjar; Robert K Ernst; Jeff H Tsai; Christopher B Wilson; Samuel I Miller
Journal:  Nat Immunol       Date:  2002-03-25       Impact factor: 25.606

2.  Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine.

Authors:  Wendell D Zollinger; Mikhail A Donets; Deborah H Schmiel; Valerian B Pinto; Joseph E Labrie; Elizabeth E Moran; Brenda L Brandt; Boris Ionin; Ryan Marques; Max Wu; Ping Chen; Mark B Stoddard; Paul B Keiser
Journal:  Vaccine       Date:  2010-07-12       Impact factor: 3.641

3.  Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870.

Authors:  Oliver Koeberling; Jo Anne Welsch; Dan M Granoff
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

4.  Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.

Authors:  Victor C Hou; Oliver Koeberling; Jo Anne Welsch; Dan M Granoff
Journal:  J Infect Dis       Date:  2005-07-15       Impact factor: 5.226

5.  Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine.

Authors:  Jo Anne Welsch; Raffaella Rossi; Maurizio Comanducci; Dan M Granoff
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

Authors:  H Nøkleby; P Aavitsland; J O'Hallahan; B Feiring; S Tilman; P Oster
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

7.  Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants.

Authors:  Mark B Stoddard; Valerian Pinto; Paul B Keiser; Wendell Zollinger
Journal:  Clin Vaccine Immunol       Date:  2009-11-18

8.  The modular architecture of meningococcal factor H-binding protein.

Authors:  Peter T Beernink; Dan M Granoff
Journal:  Microbiology (Reading)       Date:  2009-07-02       Impact factor: 2.777

9.  Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.

Authors:  Peter T Beernink; Jo Anne Welsch; Michal Bar-Lev; Oliver Koeberling; Maurizio Comanducci; Dan M Granoff
Journal:  Infect Immun       Date:  2008-06-30       Impact factor: 3.441

10.  TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A.

Authors:  Susu Zughaier; Liana Steeghs; Peter van der Ley; David S Stephens
Journal:  Vaccine       Date:  2007-04-02       Impact factor: 3.641

View more
  24 in total

1.  A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Authors:  Rolando Pajon; Carolyn M Buckwalter; Kay O Johswich; Scott D Gray-Owen; Dan M Granoff
Journal:  Vaccine       Date:  2015-02-04       Impact factor: 3.641

2.  Vaccines, reverse vaccinology, and bacterial pathogenesis.

Authors:  Isabel Delany; Rino Rappuoli; Kate L Seib
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

Review 3.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.

Authors:  Davide Serruto; Matthew J Bottomley; Sanjay Ram; Marzia M Giuliani; Rino Rappuoli
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

4.  Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Heather Stefek; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

5.  Proteomic analysis and immunogenicity of Mannheimia haemolytica vesicles.

Authors:  Sahlu Ayalew; Anthony W Confer; Binu Shrestha; Amanda E Wilson; Marie Montelongo
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

Review 6.  Cell membrane-derived nanomaterials for biomedical applications.

Authors:  Ronnie H Fang; Yao Jiang; Jean C Fang; Liangfang Zhang
Journal:  Biomaterials       Date:  2017-03-01       Impact factor: 12.479

Review 7.  Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Authors:  Dan M Granoff; Sanjay Ram; Peter T Beernink
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

8.  Neisseria infection of rhesus macaques as a model to study colonization, transmission, persistence, and horizontal gene transfer.

Authors:  Nathan J Weyand; Anne M Wertheimer; Theodore R Hobbs; Jennifer L Sisko; Nyiawung A Taku; Lindsay D Gregston; Susan Clary; Dustin L Higashi; Nicolas Biais; Lewis M Brown; Shannon L Planer; Alfred W Legasse; Michael K Axthelm; Scott W Wong; Magdalene So
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.

Authors:  Eduardo Lujan; Rolando Pajon; Dan M Granoff
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

Review 10.  Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

Authors:  Lisa K McNeil; Robert J Zagursky; Shuo L Lin; Ellen Murphy; Gary W Zlotnick; Susan K Hoiseth; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.